Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Revenue

Lineage Cell Therapeutics had revenue of $1.44M in the quarter ending March 31, 2024, a decrease of -39.48%. This brings the company's revenue in the last twelve months to $8.00M, down -32.48% year-over-year. In the year 2023, Lineage Cell Therapeutics had annual revenue of $8.95M, down -39.16%.

• Revenue (ttm): $8.00M
• Revenue Growth: -32.48%
• P/S Ratio: 24.07
• Revenue / Employee: $106,707
• Employees: 75
• Market Cap: 192.60M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	8.95M	-5.76M	-39.16%
Dec 31, 2022	14.70M	10.36M	238.70%
Dec 31, 2021	4.34M	2.52M	137.73%
Dec 31, 2020	1.83M	-1.69M	-48.05%
Dec 31, 2019	3.52M	-1.47M	-29.53%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.